Pathways of inflammation and cell death in the lung: modulation by vasoactive intestinal peptide

[1]  M. Tobin.  Culmination of an era in research on the acute respiratory distress syndrome. , 2000, The New England journal of medicine.

[2]  S. Said,et al.  NMDA receptor activation: critical role in oxidant tissue injury. , 2000, Free radical biology & medicine.

[3]  M. Dragunow,et al.  Is CREB a key to neuronal survival? , 2000, Trends in Neurosciences.

[4]  M. Matthay,et al.  The acute respiratory distress syndrome. , 1996, The New England journal of medicine.

[5]  Josep M. Guerrero,et al.  Immunobiology of vasoactive intestinal peptide (VIP) , 2000, Immunology today.

[6]  E. Chi,et al.  Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS). , 1999, Journal of immunology.

[7]  R. Virmani,et al.  Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Muñoz-Elías,et al.  Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. , 1999, Journal of immunology.

[9]  S. Said,et al.  Glutamate receptors and asthmatic airway disease. , 1999, Trends in pharmacological sciences.

[10]  M. Matthay,et al.  The alveolar space is the site of intense inflammatory and profibrotic reactions in the early phase of acute respiratory distress syndrome. , 1999, Critical care medicine.

[11]  D. Pozo,et al.  Vasoactive Intestinal Peptide (VIP) and Pituitary Adenylate Cyclase-Activation Polypeptide (PACAP) Protect Mice from Lethal Endotoxemia Through the Inhibition of TNF-α and IL-6 , 1999, The Journal of Immunology.

[12]  R. Beyaert,et al.  The cytokine‐inducible zinc finger protein A20 inhibits IL‐1‐induced NF‐κB activation at the level of TRAF6 , 1999, FEBS letters.

[13]  John C Reed,et al.  Bcl-2 family proteins , 1998, Oncogene.

[14]  K. Dickman,et al.  Glutamate Toxicity in the Lung and Neuronal Cells: Prevention or Attenuation by VIP and PACAP , 1998, Annals of the New York Academy of Sciences.

[15]  E. Muñoz-Elías,et al.  Vasoactive Intestinal Peptide and Pituitary Adenylate Cyclase-activating Polypeptide Inhibit Tumor Necrosis Factor α Transcriptional Activation by Regulating Nuclear Factor-kB and cAMP Response Element-binding Protein/c-Jun* , 1998, The Journal of Biological Chemistry.

[16]  K. Kuwano,et al.  Endothelial Cell Apoptosis in Lipopolysaccharide–Induced Lung Injury in Mice , 1998, International Archives of Allergy and Immunology.

[17]  P. Baeuerle.  Pro-inflammatory signaling: Last pieces in the NF-κB puzzle? , 1998, Current Biology.

[18]  E. Chi,et al.  Neutrophil apoptosis in the acute respiratory distress syndrome. , 1997, American journal of respiratory and critical care medicine.

[19]  A. Yakovlev,et al.  Activation of CPP32-Like Caspases Contributes to Neuronal Apoptosis and Neurological Dysfunction after Traumatic Brain Injury , 1997, The Journal of Neuroscience.

[20]  C A Beltrami,et al.  Apoptosis in the failing human heart. , 1997, The New England journal of medicine.

[21]  G. Evan,et al.  A License to Kill , 1996, Cell.

[22]  S. Said.  Molecules that protect: the defense of neurons and other cells. , 1996, The Journal of clinical investigation.

[23]  S. Said,et al.  Excitotoxicity in the lung: N-methyl-D-aspartate-induced, nitric oxide-dependent, pulmonary edema is attenuated by vasoactive intestinal peptide and by inhibitors of poly(ADP-ribose) polymerase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[24]  S. Lipton,et al.  Excitatory amino acids as a final common pathway for neurologic disorders. , 1994, The New England journal of medicine.

[25]  N. Maulik,et al.  Protective role of intracoronary vasoactive intestinal peptide in ischemic and reperfused myocardium. , 1994, The Journal of pharmacology and experimental therapeutics.

[26]  F. Cerra,et al.  Multiple organ failure syndrome in the 1990s. Systemic inflammatory response and organ dysfunction. , 1994, JAMA.

[27]  S. Heinemann,et al.  Cloned glutamate receptors. , 1994, Annual review of neuroscience.

[28]  F. Alessandrini,et al.  VASOACTIVE INTESTINAL PEPTIDE ENHANCES LUNG PRESERVATION , 1993, Transplantation.

[29]  D. Choi.  Excitotoxic cell death. , 1992, Journal of neurobiology.

[30]  B. R. Misra,et al.  Vasoactive intestinal peptide, a singlet oxygen quencher. , 1990, The Journal of biological chemistry.

[31]  R. Rosenberg,et al.  Vasoactive intestinal polypeptide: abundant immunoreactivity in neural cell lines and normal nervous tissue. , 1976, Science.

[32]  V. Mutt,et al.  Polypeptide with Broad Biological Activity: Isolation from Small Intestine , 1970, Science.

[33]  Said Si.  Vasoactive substances in the lung. , 1967 .